Jun 09, 2021 11:31 JST

Source: Eisai

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

TOKYO, Jun 09, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).

Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

For more information, visit https://www.eisai.com/news/2021/news202143.html.

Source: Eisai
Sectors: BioTech

Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 15 2021 08:00 JST
 
Eisai Receives Special Prize at Platinum Career Award 2021
June 09 2021 12:44 JST
 
Biogen and Eisai launch initiatives to help patients with Alzheimer's disease access ADUHELM
June 08 2021 13:09 JST
 
FDA grants accelerated approval for ADUHELM as the first and only Alzheimer's disease treatment to address a defining pathology of the disease
June 08 2021 08:47 JST
 
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib
June 08 2021 07:19 JST
 
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
May 31 2021 17:54 JST
 
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting
May 20 2021 08:36 JST
 
Anticancer Agent "Remitoro Intravenous Drip Infusion 300 microgram" (Denileukin Diftitox (Genetical Recombination)) Launched in Japan
May 19 2021 11:27 JST
 
Eisai and National Cancer Center Commence Joint Research and Development Project
May 14 2021 16:48 JST
 
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11 2021 09:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>